Abstract
In this chapter, we discuss the epidemiology of renal cell carcinoma including its risk factors and current demographic composition. Additionally, changes over time in particular with the increasing use of CT scanning are discussed. Evidence for screening protocols for specific populations at risk, such as those with genetic syndromes, is analyzed. Finally, the literature that led to the development and continued refinement of the TNM and other staging systems is reviewed.
Keywords
- Renal Cell Carcinoma
- Inferior Vena Cava
- Autosomal Dominant Polycystic Kidney Disease
- Inferior Vena Cava Thrombus
- Renal Cell Carcinoma Risk
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12):2893–917.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.
Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist. 2003;8(6): 541–52.
Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. NEJM. 1996;335(12):865–75.
Storkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, et al. Classification of renal cell carcinoma: workgroup no. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80(5):987–9.
Patard JJ. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2004;23(12):2763–71.
Beck SDW. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol. 2003;11(1): 71–7.
Dall’Oglio MF, Antunes AA, Pompeo AC, Mosconi A, Leite KR, Srougi M. Prognostic relevance of the histological subtype of renal cell carcinoma. Int Braz J Urol. 2008;34(1):3–8.
Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2011.
Mindrup SR, Pierre JS, Dahmoush L, Konety BR. The prevalence of renal cell carcinoma diagnosed at autopsy. BJU Int. 2005;95(1):31–3.
Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration. Cancer. 2008;113(1):78–83.
Chow WH, Devesa SS, Warren JL, Fraumeni Jr JF. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281(17):1628–31.
Mariotto AB, Robin Yabroff K, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. JNCI J Natl Cancer Inst. 2011;103(2):117–28.
Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma – age and stage characterization and clinical implications: study of 1092 patients (1982–1997). Urology. 2000;56(1):58–62.
Verhoest G, Veillard D, Guillé F, Taille ADL, Salomon L, Abbou CC, et al. Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. Eur Urol. 2007;51(5): 1298–305.
Aron M, Nguyen MM, Stein RJ, Gill IS. Impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur Urol. 2008;54(1):133–42.
Silverberg E, Grant RN. Cancer statistics, 1970. CA Cancer J Clin. 1970;20(1):11–23.
Boring CC, Squires TS, Tong T. Cancer statistics, 1991. Bol Asoc Med P R. 1991;83(6):225–42.
Woldrich JM, Mallin K, Ritchey J, Carroll PR, Kane CJ. Sex differences in renal cell cancer presentation and survival: an analysis of the National Cancer Database, 1993–2004. J Urol. 2008;179(5):1709–13. Discussion 13.
Vaishampayan UN, Do H, Hussain M, Schwartz K. Racial disparity in incidence patterns and outcome of kidney cancer. Urology. 2003;62(6):1012–7.
Stafford HS, Saltzstein SL, Shimasaki S, Sanders C, Downs TM, Sadler GR. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol. 2008;179(5):1704–8.
Sankin A, Cohen J, Wang H, Macchia RJ, Karanikolas N. Rate of renal cell carcinoma subtypes in different races. Int Braz J Urol. 2011;37(1):29–32. Discussion 3–4.
Berndt SI, Carter HB, Schoenberg MP, Newschaffer CJ. Disparities in treatment and outcome for renal cell cancer among older black and white patients. J Clin Oncol. 2007;25(24):3589–95.
Saigal CS, Deibert CM, Lai J, Schonlau M. Disparities in the treatment of patients with IL-2 for metastatic renal cell carcinoma. Urol Oncol Semin Orig Invest. 2010;28(3):308–13.
Broecker B. Non-Wilms’ renal tumors in children. Urol Clin North Am. 2000;27(3):463–9. ix.
Kubo M, Iwashita K, Oyachi N, Oyama T, Yamamoto T. Two different types of infantile renal cell carcinomas associated with tuberous sclerosis. J Pediatr Surg. 2011;46(10):e37–41.
Geller JI, Argani P, Adeniran A, Hampton E, De Marzo A, Hicks J, et al. Translocation renal cell carcinoma. Cancer. 2008;112(7):1607–16.
Argani P, Ladanyi M. Translocation carcinomas of the kidney. Clin Lab Med. 2005;25(2):363–78.
Yamaguchi T, Fukuda T, Uetani M, Hayashi K, Kurosaki N, Maeda H, et al. Renal cell carcinoma in a patient with Beckwith-Wiedemann syndrome. Pediatr Radiol. 1996;26(5):312–4.
Indolfi P. Renal cell carcinoma in children: a clinicopathologic study. J Clin Oncol. 2003;21(3):530–5.
Sanchez-Ortiz RF, Rosser CJ, Madsen LT, Swanson DA, Wood CG. Young age is an independent prognostic factor for survival of sporadic renal cell carcinoma. J Urol. 2004;171(6 Pt 1):2160–5.
La Vecchia C, Negri E, D’Avanzo B, Franceschi S. Smoking and renal cell carcinoma. Cancer Res. 1990;50(17):5231–3.
Yuan JM, Castelao JE, Gago-Dominguez M, Yu MC, Ross RK. Tobacco use in relation to renal cell carcinoma. Cancer Epidemiol Biomark Prev. 1998;7(5): 429–33.
McLaughlin JK, Hrubec Z, Heineman EF, Blot WJ, Fraumeni Jr JF. Renal cancer and cigarette smoking in a 26-year followup of U.S. veterans. Public Health Rep. 1990;105(5):535–7.
Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer. 2005;114(1):101–8.
McLaughlin JK, Mandel JS, Blot WJ, Schuman LM, Mehl ES, Fraumeni Jr JF. A population–based case–control study of renal cell carcinoma. J Natl Cancer Inst. 1984;72(2):275–84.
Yuan JM, Castelao JE, Gago-Dominguez M, Ross RK, Yu MC. Hypertension, obesity and their medications in relation to renal cell carcinoma. Br J Cancer. 1998;77(9):1508–13.
Chow WH, Gridley G, Fraumeni Jr JF, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343(18):1305–11.
Bergstrom A, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A. Obesity and renal cell cancer–a quantitative review. Br J Cancer. 2001;85(7):984–90.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78.
Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579–91.
Moyad MA. Obesity, interrelated mechanisms, and exposures and kidney cancer. Semin Urol Oncol. 2001;19(4):270–9.
Lowrance WT, Thompson RH, Yee DS, Kaag M, Donat SM, Russo P. Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies. BJU Int. 2010;105(1):16–20.
Ogden CL. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA Journal Am Med Assoc. 2006;295(13):1549–55.
Heath Jr CW, Lally CA, Calle EE, McLaughlin JK, Thun MJ. Hypertension, diuretics, and antihypertensive medications as possible risk factors for renal cell cancer. Am J Epidemiol. 1997;145(7):607–13.
Shapiro JA, Williams MA, Weiss NS, Stergachis A, LaCroix AZ, Barlow WE. Hypertension, antihypertensive medication use, and risk of renal cell carcinoma. Am J Epidemiol. 1999;149(6):521–30.
Grossman E, Messerli FH, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med. 2002;112(6):479–86.
Colt JS, Schwartz K, Graubard BI, Davis F, Ruterbusch J, DiGaetano R, et al. Hypertension and risk of renal cell carcinoma among White and Black Americans. Epidemiology. 2011;22(6):797–804.
Grossman E. Antihypertensive therapy and the risk of malignancies. Eur Hear J. 2001;22(15):1343–52.
Gago-Dominguez M, Yuan JM, Castelao JE, Ross RK, Yu MC. Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer. 1999;81(3): 542–8.
Cho E, Curhan G, Hankinson SE, Kantoff P, Atkins MB, Stampfer M, et al. Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med. 2011;171(16):1487–93.
Rashidkhani B, Lindblad P, Wolk A. Fruits, vegetables and risk of renal cell carcinoma: a prospective study of Swedish women. Int J Cancer. 2005; 113(3):451–5.
Lee JE, Mannisto S, Spiegelman D, Hunter DJ, Bernstein L, van den Brandt PA, et al. Intakes of fruit, vegetables, and carotenoids and renal cell cancer risk: a pooled analysis of 13 prospective studies. Cancer Epidemiol Biomark Prev. 2009;18(6):1730–9.
Handa K, Kreiger N. Diet patterns and the risk of renal cell carcinoma. Public Health Nutr. 2007;5(06): 757–67.
Daniel CR, Schwartz KL, Colt JS, Dong LM, Ruterbusch JJ, Purdue MP, et al. Meat-cooking mutagens and risk of renal cell carcinoma. Br J Cancer. 2011;105(7):1096–104.
Daniel CR, Cross AJ, Graubard BI, Park Y, Ward MH, Rothman N, et al. Large prospective investigation of meat intake, related mutagens, and risk of renal cell carcinoma. Am J Clin Nutr. 2011;95(1): 155–62.
Lee JE, Hunter DJ, Spiegelman D, Adami HO, Albanes D, Bernstein L, et al. Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies. JNCI J Natl Cancer Inst. 2007;99(10): 801–10.
Lee JE, Hunter DJ, Spiegelman D, Adami HO, Bernstein L, van den Brandt PA, et al. Intakes of coffee, tea, milk, soda and juice and renal cell cancer in a pooled analysis of 13 prospective studies. Int J Cancer. 2007;121(10):2246–53.
Bruning T, Pesch B, Wiesenhutter B, Rabstein S, Lammert M, Baumuller A, et al. Renal cell cancer risk and occupational exposure to trichloroethylene: results of a consecutive case-control study in Arnsberg, Germany. Am J Indus Med. 2003;43(3): 274–85.
Vamvakas S, Bruning T, Thomasson B, Lammert M, Baumuller A, Bolt HM, et al. Renal cell cancer correlated with occupational exposure to trichloroethene. J Cancer Res Clin Oncol. 1998;124(7):374–82.
Gates TJ. Screening for cancer: evaluating the evidence. Am Fam Physician. 2001;63(3):513–22.
Leslie JA, Prihoda T, Thompson IM. Serendipitous renal cell carcinoma in the post-CT era: continued evidence in improved outcomes. Urol Oncol. 2003; 21(1):39–44.
Parsons JK, Schoenberg MS, Carter HB. Incidental renal tumors: casting doubt on the efficacy of early intervention. Urology. 2001;57(6):1013–5.
Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98(18):1331–4.
Murakami S, Igarashi T, Hara S, Shimazaki J. Strategies for asymptomatic microscopic hematuria: a prospective study of 1034 patients. J Urol. 1990; 144(1):99–101.
Warshauer DM, McCarthy SM, Street L, Bookbinder MJ, Glickman MG, Richter J, et al. Detection of renal masses: sensitivities and specificities of excretory urography/linear tomography, US, and CT. Radiology. 1988;169(2):363–5.
Malaeb BS, Martin DJ, Littooy FN, Lotan Y, Waters WB, Flanigan RC, et al. The utility of screening renal ultrasonography: identifying renal cell carcinoma in an elderly asymptomatic population. BJU Int. 2005;95(7):977–81.
Mihara S, Kuroda K, Yoshioka R, Koyama W. Early detection of renal cell carcinoma by ultrasonographic screening–based on the results of 13 years screening in Japan. Ultrasound Med Biol. 1999;25(7): 1033–9.
Brown EA. Renal tumours in dialysis patients: who should we screen? Nephron Clin Pract. 2004;97(1): c3–4.
Ishikawa I, Honda R, Yamada Y, Kakuma T. Renal cell carcinoma detected by screening shows better patient survival than that detected following symptoms in dialysis patients. Ther Apher Dial. 2004; 8(6):468–73.
Sarasin FP, Wong JB, Levey AS, Meyer KB. Screening for acquired cystic kidney disease: a decision analytic perspective. Kidney Int. 1995;48(1): 207–19.
Neuzillet Y, Lay F, Luccioni A, Daniel L, Berland Y, Coulange C, et al. De novo renal cell carcinoma of native kidney in renal transplant recipients. Cancer. 2005;103(2):251–7.
Moudouni SM, Lakmichi A, Tligui M, Rafii A, Tchala K, Haab F, et al. Renal cell carcinoma of native kidney in renal transplant recipients. BJU Int. 2006;98(2): 298–302.
Denton MD, Magee CC, Ovuworie C, Mauiyyedi S, Pascual M, Colvin RB, et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. Kidney Int. 2002;61(6):2201–9.
Fenton JJ, Weiss NS. Screening computed tomography: will it result in overdiagnosis of renal carcinoma? Cancer. 2004;100(5):986–90.
Hoque MO, Begum S, Topaloglu O, Jeronimo C, Mambo E, Westra WH, et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res. 2004;64(15):5511–7.
Dubiel JP, Bielecki A, Ciba T. Effects of Sadamin and Complamin on left ventricular function. Pol Tyg Lek. 1973;28(12):430–3.
Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. Lancet. 2003;361(9374):2059–67.
Zbar B. Von Hippel-Lindau disease and sporadic renal cell carcinoma. Cancer Surv. 1995;25:219–32.
Choyke PL, Glenn GM, Walther MM, Zbar B, Weiss GH, Alexander RB, et al. The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients. AJR Am J Roentgenol. 1992;159(6):1229–34.
Lendvay TS, Marshall FF. The tuberous sclerosis complex and its highly variable manifestations. J Urol. 2003;169(5):1635–42.
Rakowski SK, Winterkorn EB, Paul E, Steele DJ, Halpern EF, Thiele EA. Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors. Kidney Int. 2006;70(10):1777–82.
Liu MY, Poellinger L, Walker CL. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Cancer Res. 2003;63(10):2675–80.
Gregoire JR, Torres VE, Holley KE, Farrow GM. Renal epithelial hyperplastic and neoplastic proliferation in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1987;9(1):27–38.
Mosetti MA, Leonardou P, Motohara T, Kanematsu M, Armao D, Semelka RC. Autosomal dominant polycystic kidney disease: MR imaging evaluation using current techniques. J Magn Reson Imaging. 2003;18(2):210–5.
Gupta S, Seith A, Sud K, Kohli HS, Singh SK, Sakhuja V, et al. CT in the evaluation of complicated autosomal dominant polycystic kidney disease. Acta Radiol. 2000;41(3):280–4.
Reed B, Nobakht E, Dadgar S, Bekheirnia MR, Masoumi A, Belibi F, et al. Renal ultrasonographic evaluation in children at risk of autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2010;56(1):50–6.
Zbar B, Glenn G, Merino M, Middelton L, Peterson J, Toro J, et al. Familial renal carcinoma: clinical evaluation, clinical subtypes and risk of renal carcinoma development. J Urol. 2007;177(2):461–5. Discussion 5.
Gospodarowicz MK, Miller D, Groome PA, Greene FL, Logan PA, Sobin LH. The process for continuous improvement of the TNM classification. Cancer. 2004;100(1):1–5.
Flocks RH, Kadesky MC. Malignant neoplasms of the kidney; an analysis of 353 patients followed five years or more. J Urol. 1958;79(2):196–201.
Harmer M. NM classification of malignant tumors. 3rd ed. Geneva: International Union Against Cancer; 1974.
Edge SB, editor. AJCC cancer staging manual. 7th ed. Chicago: Springer; 2010.
Howard GE, Wood CG. Staging refinements in renal cell carcinoma. Curr Opin Urol. 2006;16(5): 317–20.
Ficarra V, Novara G, Galfano A, Artibani W. Neoplasm staging and organ-confined renal cell carcinoma: a systematic review. Eur Urol. 2004; 46(5): 559–64.
Greene FL, editor. AJCC cancer staging manual. 6th ed. Chicago: Springer; 2002.
Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol. 1999;162(6):1930–3.
Ficarra V, Schips L, Guille F, Li G, De La Taille A, Prayer Galetti T, et al. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer. 2005;104(5):968–74.
Mitchell RE, Gilbert SM, Murphy AM, Olsson CA, Benson MC, McKiernan JM. Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumors 4 cm or larger. Urology. 2006;67(2):260–4.
Zisman A, Pantuck AJ, Chao D, Dorey F, Said JW, Gitlitz BJ, et al. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. J Urol. 2001;166(1):54–8.
Cheville JC, Blute ML, Zincke H, Lohse CM, Weaver AL. Stage pT1 conventional (clear cell) renal cell carcinoma: pathological features associated with cancer specific survival. J Urol. 2001; 166(2):453–6.
Ficarra V, Guille F, Schips L, de la Taille A, Prayer Galetti T, Tostain J, et al. Proposal for revision of the TNM classification system for renal cell carcinoma. Cancer. 2005;104(10):2116–23.
Klatte T, Patard JJ, Goel RH, Kleid MD, Guille F, Lobel B, et al. Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol. 2007;178(1):35–40. Discussion.
Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Kwon ED, et al. pT2 classification for renal cell carcinoma. Can its accuracy be improved? J Urol. 2005;173(2):380–4.
Murphy AM, Gilbert SM, Katz AE, Goluboff ET, Sawczuk IS, Olsson CA, et al. Re-evaluation of the tumour-node-metastasis staging of locally advanced renal cortical tumours: absolute size (T2) is more significant than renal capsular invasion (T3a). BJU Int. 2005;95(1):27–30.
Lam JS, Klatte T, Patard JJ, Goel RH, Guille F, Lobel B, et al. Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol. 2007;52(1):155–62.
Siemer S, Lehmann J, Loch A, Becker F, Stein U, Schneider G, et al. Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol. 2005;173(1):33–7.
Bertini R, Roscigno M, Freschi M, Strada E, Petralia G, Pasta A, et al. Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases. J Urol. 2009;181(5):2027–32.
Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, et al. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? J Urol. 2005;174(4 Pt 1):1218–21.
Thompson RH, Cheville JC, Lohse CM, Webster WS, Zincke H, Kwon ED, et al. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer. 2005;104(1):53–60.
Leibovich BC, Cheville JC, Lohse CM, Zincke H, Kwon ED, Frank I, et al. Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved? J Urol. 2005;173(3):716–9.
Margulis V, Tamboli P, Matin SF, Meisner M, Swanson DA, Wood CG. Redefining pT3 renal cell carcinoma in the modern era: a proposal for a revision of the current TNM primary tumor classification system. Cancer. 2007;109(12):2439–44.
da Costa WH, Moniz RR, da Cunha IW, Fonseca FP, Guimaraes GC, de Cassio Zequi S. Impact of renal vein invasion and fat invasion in pT3a renal cell carcinoma. BJU Int. 2012;109(4):544–8.
Ficarra V, Righetti R, D’Amico A, Rubilotta E, Novella G, Malossini G, et al. Renal vein and vena cava involvement does not affect prognosis in patients with renal cell carcinoma. Oncology. 2001;61(1):10–5.
Whitson JM, Reese AC, Meng MV. Population based analysis of survival in patients with renal cell carcinoma and venous tumor thrombus. Urol Oncol. 2011 Jul 25.
Rabbani F, Hakimian P, Reuter VE, Simmons R, Russo P. Renal vein or inferior vena caval extension in patients with renal cortical tumors: impact of tumor histology. J Urol. 2004;171(3):1057–61.
Wagner B, Patard JJ, Mejean A, Bensalah K, Verhoest G, Zigeuner R, et al. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol. 2009;55(2):452–9.
Kim HL, Zisman A, Han KR, Figlin RA, Belldegrun AS. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol. 2004;171 (2 Pt 1):588–91.
Moinzadeh A, Libertino JA. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? J Urol. 2004;171(2 Pt 1): 598–601.
Nesbitt JC, Soltero ER, Dinney CP, Walsh GL, Schrump DS, Swanson DA, et al. Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. Ann Thorac Surg. 1997;63(6): 1592–600.
Haferkamp A, Bastian PJ, Jakobi H, Pritsch M, Pfitzenmaier J, Albers P, et al. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup. J Urol. 2007;177(5): 1703–8.
Han KR, Bui MH, Pantuck AJ, Freitas DG, Leibovich BC, Dorey FJ, et al. TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol. 2003;169(3):899–903. Discussion 4.
Thompson RH, Leibovich BC, Cheville JC, Lohse CM, Frank I, Kwon ED, et al. Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a? J Urol. 2005;173(3): 918–21.
Terrone C, Cracco C, Porpiglia F, Bollito E, Scoffone C, Poggio M, et al. Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol. 2006;49(2):324–31.
Dimashkieh HH, Lohse CM, Blute ML, Kwon ED, Leibovich BC, Cheville JC. Extranodal extension in regional lymph nodes is associated with outcome in patients with renal cell carcinoma. J Urol. 2006; 176(5):1978–82. Discussion 82–3.
Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol. 2003;169(6):2076–83.
Novara G, Ficarra V, Antonelli A, Artibani W, Bertini R, Carini M, et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol. 2010;58(4):588–95.
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530–40.
Lee C, You D, Park J, Jeong IG, Song C, Hong JH, et al. Validation of the 2009 TNM classification for renal cell carcinoma: comparison with the 2002 TNM classification by concordance index. Korean J Urol. 2011;52(8):524–30.
Uzzo RG, Cherullo EE, Myles J, Novick AC. Renal cell carcinoma invading the urinary collecting system: implications for staging. J Urol. 2002;167(6): 2392–6.
Verhoest G, Avakian R, Bensalah K, Thuret R, Ficarra V, Artibani W, et al. Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma. J Urol. 2009;182(3):854–9.
Patard JJ, Leray E, Cindolo L, Ficarra V, Rodriguez A, De La Taille A, et al. Multi-institutional validation of a symptom based classification for renal cell carcinoma. J Urol. 2004;172(3):858–62.
Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19(6):1649–57.
Patard JJ, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004;22(16):3316–22.
Ficarra V, Novara G, Galfano A, Brunelli M, Cavalleri S, Martignoni G, et al. The ‘stage, size, grade and necrosis’ score is more accurate than the University of California Los Angeles integrated staging system for predicting cancer-specific survival in patients with clear cell renal cell carcinoma. BJU Int. 2009;103(2):165–70.
Guinan P, Sobin LH, Albaga F, et al. TNM staging of renal carcinoma: workgroup no. 3. Cancer. 1997;80(5):992–3.
Green FL, Page D, Morrow M. AJCC cancer staging manual. 6th ed. New York: Springer; 2010.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Lipsky, M.J., Deibert, C.M., McKiernan, J.M. (2013). Epidemiology, Screening, and Clinical Staging. In: Libertino, J. (eds) Renal Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7236-0_1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7236-0_1
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-7235-3
Online ISBN: 978-1-4614-7236-0
eBook Packages: MedicineMedicine (R0)